Background Chronic refractory cough (CRC) is a difficult problem to treat. Speech pathology
treatment (SPT) improves symptoms but resolution is incomplete. Centrally acting …

ABSTRACT Introduction: Chronic Cough (CC) is common and often associated with
significant comorbidity and decreased quality of life. In up to 50% of cases, the cough is …

Background Refractory chronic cough causes substantial symptoms and quality-of-life
impairment. Similarities between central reflex sensitisation in refractory chronic cough and …

Key Clinical Points Chronic Cough Chronic cough (cough> 8 weeks in duration) is common
and can be disabling. Chronic cough is a feature of many respiratory diseases, and common …

Chronic refractory cough (CRC) is defined as a cough that persists despite guideline based
treatment. It is seen in 20-46% of patients presenting to specialist cough clinics and it has a …

Background Unexplained chronic cough (UCC) causes significant impairments in quality of
life. Effective assessment and treatment approaches are needed for UCC. Methods This …

Background We present study designs, dose selection and preliminary patient
characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in …

Rationale Speech language pathology is an effective management intervention for chronic
cough that persists despite medical treatment. The mechanism behind the improvement has …

Background Gefapixant is an oral P2X 3 receptor antagonist that has previously shown
efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore …

Importance Gefapixant represents an emerging therapy for patients with refractory or
unexplained chronic cough. Objective To evaluate the efficacy and tolerability of gefapixant …